Guest lecture by Michael Holinstat | Development of CS585 as a novel drug for the prevention of thrombosis

Prof Michael Holinstat PhD (Dept Pharmacology, University of Michigan, USA) will give a guest lecture  at Sanquin, Amsterdam.

Title: Development of CS585 as a novel drug for the prevention of thrombosis.

Host: Rick Kapur

Add to calendar

Join online

Research:
Dr. Holinstat’s research interests focus on understanding lipid, lipoxygenase, and oxygenase regulation of platelet signaling and function and how it relates to regulation of hemostasis and thrombosis. Dr. Holinstat has received numerous patents in the US, EU, and Japan for various therapeutic discoveries to treat cardiovascular disease and has developed a number of first-in-class antiplatelet drugs including the 12-lipoxygenase inhibitor (ML355) and prostacyclin receptor agonist (CS585) that are both in various stages of clinical development for thrombosis.

CV

Dr. Holinstat is a Professor in the Departments of Pharmacology, Internal Medicine (Division of Cardiovascular Medicine), and Vascular Surgery. Dr. Holinstat also serves as the inaugural Director of the Platelet Physiology and Pharmacology Platelet Core at the University of Michigan. His service to the research community includes the sub-committee on Hemostasis and Thrombosis at the American Society for Hematology and the Director for the NIH CTSI-funded T32 training grant in clinical research. Dr. Holinstat has received several national awards including the Kenneth M. Brinkhous Young Investigator Prize in Thrombosis from the American Heart Association in 2012, the Young Investigator Award in Structure-Function from the Eicosanoid Research Foundation in 2013, and the Distinguished Educator: Mentorship Innovation Award from the Association for Clinical and Translational Science (ACTS) in 2024.